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ABSTRACT
Due to their high affinity and specificity, aptamers
have been widely used as effective inhibitors in clin-
ical applications. However, the ability to activate pro-
tein function through aptamer-protein interaction has
not been well-elucidated. To investigate their poten-
tial as target-specific agonists, we used SELEX to
generate aptamers to the insulin receptor (IR) and
identified an agonistic aptamer named IR-A48 that
specifically binds to IR, but not to IGF-1 receptor. De-
spite its capacity to stimulate IR autophosphoryla-
tion, similar to insulin, we found that IR-A48 not only
binds to an allosteric site distinct from the insulin
binding site, but also preferentially induces Y1150
phosphorylation in the IR kinase domain. Moreover,
Y1150-biased phosphorylation induced by IR-A48 se-
lectively activates specific signaling pathways down-
stream of IR. In contrast to insulin-mediated activa-
tion of IR, IR-A48 binding has little effect on the MAPK
pathway and proliferation of cancer cells. Instead,
AKT S473 phosphorylation is highly stimulated by
IR-A48, resulting in increased glucose uptake both in
vitro and in vivo. Here, we present IR-A48 as a biased
agonist able to selectively induce the metabolic activ-
ity of IR through allosteric binding. Furthermore, our
study also suggests that aptamers can be a promis-
ing tool for developing artificial biased agonists to
targeted receptors.
INTRODUCTION
Aptamers are single-strand oligonucleotides artificially iso-
lated by an in vitro selection process called Systematic Evo-
lution of Ligands by EXponential Enrichment (SELEX)
(1,2). Due to their unique three-dimensional structure, ap-
tamers can strongly interact with specific regions of target
molecules. Based on this property, aptamers are widely used
in many applications as target-specific binders with high
affinity and specificity.
Most efforts to develop functional aptamers focused on
their inhibitory effects on target molecules. In clinical ap-
plications, a variety of inhibitory aptamers have been de-
veloped to treat diseases by effectively disrupting the ac-
tion of target molecules (e.g. Macugen, an anti-VEGF ap-
tamer and AS1411, an anti-nucleolin aptamer) (3–5). How-
ever, given that molecular interaction is necessarily followed
by conformational change, it is reasonable to assume that
aptamer–protein interaction can also activate the function
of protein if it induces the proper conformational change.
Thus, in theory, aptamers have the potential to act as func-
tional agonists by mimicking specific protein–protein inter-
actions. However, the development of agonistic aptamers
that directly activate target functions remains a challenging
task at present.
For the proof of concept that the development of ago-
nistic aptamers is possible, we generated aptamers against
membrane receptors and screened them by analyzing recep-
tor activation. Membrane receptors are ideal targets for the
development of agonistic aptamers. First, aptamers against
the extracellular domains of membrane receptors do not
need to be capable of membrane penetration. Generally,
negatively charged oligonucleotides such as aptamers can-
not penetrate plasma membranes without delivery systems
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(6). Second, the development of receptor modulators is a
valuable tool for drug discovery because membrane pro-
teins account for ∼60% of all approved drug targets (7,8).
In this study, we chose the insulin receptor (IR) as the
target receptor for the development of an aptamer agonist.
The IR consists of two extracellular -subunits that contain
insulin binding sites and two transmembrane -subunits
with kinase activity. Insulin binding to the IR results in au-
tophosphorylation of intracellular tyrosine residues, which
increases IR kinase activity and initiates a cascade of intra-
cellular signaling events (9). IR signaling mediates a wide
range of metabolic and mitogenic functions and, impor-
tantly, plays a critical role in the homeostasis of blood glu-
cose by regulating glucose transporter 4 (GLUT4) translo-
cation to the cell surface in adipose tissue and muscle (10).
Diabetes mellitus develops when GLUT4 translocation is
impaired by insulin resistance or insufficient insulin (11).
Accordingly, the development of agonists able to effectively
stimulate IR activity is considered an important goal for di-
abetes care.
Here, we present an agonistic IR aptamer, IR-A48, which
binds to an allosteric site of the IR that is distinct from
the insulin binding site. Interestingly, we found that IR-A48
not only preferentially stimulates Y1150 phosphorylation
in the IR kinase domain, but also has biased activity to-
ward the IRS-AKT S473 pathway, stimulating glucose up-
take rather than activation of theMAPK pathway and sub-
sequent cell proliferation. Our findings suggest that IR-A48
is a biased agonist able to specifically regulate the insulin
signaling pathway (i.e. metabolic over mitogenic activity).
These findings comprise a pilot study that provides the ra-
tionale for the development of allosteric aptamer agonists
able to selectively regulate the functions of various recep-
tors.
MATERIALS AND METHODS
Reagents and antibodies
Aptamers were synthesized from Aptamer Science, Inc.
(Pohang, Korea) or ST Pharm (Siheung, Korea). Bovine
insulin, FITC-labeled insulin, LY-294002, dexametha-
sone and 3-isobutyl-1-methylxanthine (IBMX) were
purchased from Sigma-Aldrich (St Louis, MO, USA).
Phospho-peptides for ELISA assay were synthesized by
Selleckchem (Houston, TX, USA). Anti-IR -subunit
(C-19), anti-IGF-1R -subunit (C-20), anti-phospho-IR
(10C3, Y1150/Y1151), anti-phospho-IRS1 (Y632) and
anti-phospho-Shc (Y239/Y240) antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-phospho-tyrosine (4G10), anti-phospho-IRS1 (Y612)
human/(Y608) mouse and anti-phospho-IR (Y1146) an-
tibodies were purchased from Millipore (Darmstadt, Ger-
many). Anti-phospho-IR (Y960), anti-phospho-IR (pAb,
Y1150/Y1151), anti-phospho-IR (Y1316), anti-phospho-
IR (Y1322), anti-phospho-IR (Y1146/Y1150/Y1151),
alkaline phosphatase (AP)-labeled anti-rabbit/mouse
antibodies and Disodium 3-(5’-chloro-4-methoxyspiro[1,2-
dioxetane-3,2’-tricyclo[3.3.1.13,7]decan]-4-yl)phenyl
phosphate (CSPD) substrate for AP were purchased from
Invitrogen (Carlsbad, CA, USA). Anti-phospho-AKT
(S473), anti-phospho-AKT (T308), anti-phospho-ERK1/2
(T202/Y204), anti-phospho-FoxO1/3a (T24/T32) and
anti-phospho-AS160 (T642) antibodies were purchased
from Cell Signaling Technology (Danvers, MA, USA).
IRdye 800-conjugated anti-rabbit/mouse antibodies were
purchased from Rockland (Limerick, PA, USA) and HRP-
conjugated anti-rabbit/mouse antibodies were purchased
from KPL (Gaithersburg, MD, USA).
In vitro selection of IR aptamers
To identify IR-specific aptamers, we performed a SE-
LEX process as previously described (12). Briefly,
a modified single-stranded DNA (ssDNA) library
with a 40mer random region (N40) containing 5-
[N-(1-naphthylmethyl)carboxamide]-2′-deoxyuridine
(Nap-dU) in place of dT was prepared. The random
regions were flanked by 20mer constant regions for
polymerase chain reaction (PCR) with the following
sequence: 5′-TATGAGTGACCGTCCGCCTG-N40-
CAGCCACACCACCAGCCAAA-3′. The ssDNA library
was incubated with his-tagged recombinant IR extracel-
lular domain (His 28-Lys 944) (R&S Systems, MN, USA)
in selection buffer [40 mM HEPES (pH 7.5), 102 mM
NaCl, 5 mM KCl, 5 mM MgCl2 and 0.05% Tween-20].
After ssDNA binding, IR proteins were partitioned by
immobilizing them on Dynabeads TALON (Invitrogen,
Carlsbad, CA, USA) and unbound ssDNAs were removed
by washing with selection buffer. ssDNAs were extracted
and amplified by conventional PCR using a 5′-OH terminal
biotinylated reverse primer. After eight rounds of SELEX,
the enriched ssDNA pool was cloned and sequenced.
Aptamer binding assay
The binding affinity of the aptamer to the extracellular do-
mains of IR (His 28-Lys 944) and IGF-1R (Gln 31Asn 932)
was analyzed by filter binding assay. First, the 5′-end of
the aptamer was labeled with [-32P] adenosine triphos-
phate. After heating at 95◦C for 3 min and then slow cool-
ing to 37◦C at 0.1◦C/s in binding buffer [40 mM HEPES
(pH 7.5), 120 mM NaCl, 5 mM KCl, 5 mM MgCl2 and
0.002%Tween-20] to reconstitute the aptamer structure, the
aptamer was incubated with purified recombinant IR or
IGF-1R at various concentrations for 30 min at 37◦C. To
pull down the aptamer–protein complexes, the solution was
incubated with Zorbax silica beads (Agilent, CA, USA) for
1 min with shaking. The aptamer–protein complex bound
to the beads was partitioned through nitrocellulose filter
plates (Millipore, MA, USA) and washed in binding buffer
to remove unbound aptamer. The amount of radiolabeled
aptamer that interacted with proteins was detected by ex-
posure to photographic film and quantified using a Fuji
FLA-5000 Image Analyzer (Tokyo, Japan). The dissocia-
tion constant (Kd) of the aptamers was determined by fitting
the binding data to a one-site saturation equation using the
SigmaPlot program.
Cell culture and adipocyte differentiation
HEK293 and 3T3-L1 cells were purchased from ATCC
(Manassas, VA, USA), and MCF-7 cells were purchased
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from KCLB (Korea Cell Line Bank, Seoul), and Rat-1
cells overexpressing human IR were kindly provided by Dr
Nicholas J. G. Webster from the University of California,
San Diego. HEK293, Rat-1/hIR and MCF-7 cells were
maintained in high glucose Dulbecco’s modified Eagle’s
medium (DMEM) with 10% (vol/vol) fetal bovine serum
(FBS, Lonza) and 3T3-L1 pre-adipocytes were maintained
in high glucoseDMEMwith 10% bovine serum (BS,Gibco)
at 37◦Cunder a humidified atmosphere containing 5%CO2.
For adipocyte differentiation, 3T3-L1 pre-adipocytes were
cultured for 2 days past confluence. Differentiation was ini-
tiated by changing themedium toDMEMcontaining 1M
dexamethasone, 500 nM IBMX, 850 nM insulin and 10%
FBS. After 2 days, the medium was replaced with DMEM
containing 850 nM insulin and 10% FBS and then incu-
bated for two additional days. Finally, the medium was
changed to DMEM containing only 10% FBS and incu-
bated for 4–5 days until at least 90% of the cell population
exhibited accumulation of lipid droplets.
Cell experiments
Before insulin or aptamer stimulation, the cells were incu-
bated in DMEMwithout FBS for 3 h and then incubated in
Krebs-Ringer HEPES buffer [25 mMHEPES (pH 7.4), 120
mMNaCl, 5 mMKCl, 1.2 mMMgSO4, 1.3 mMCaCl2 and
1.3 mM KH2PO4] for 1 h. For the cell experiments, the ap-
tamers and insulin were prepared in Krebs-Ringer HEPES
buffer. All aptamer samples were heated for 5 min at 95◦C
and slowly cooled to room temperature to reconstitute the
tertiary structure of the aptamer.
Western blot and immunoprecipitation
To prepare total cell lysate, harvested cells were lysed in
lysis buffer [50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1
mM ethylenediaminetetraacetic acid (EDTA), 20 mMNaF,
10 mM -glycerophosphate, 2 mM Na3VO4, 1 mM PMSF,
10% glycerol, 1% Triton-X and protease inhibitor cock-
tails]. Soluble cell lysate was isolated by centrifugation at 14
000 rpm for 15 min at 4◦C. For immunoprecipitation, the
isolated cell lysate was incubated with 2 g of antibodies
overnight at 4◦C and Protein A agarose beads were added
to pull down the antibodies. After sodiumdodecyl sulphate-
polyacrylamide gel electrophoresis, the proteins were trans-
ferred to membranes and incubated in primary antibodies
overnight at 4◦C. Blotting was performed using a LI-COR
Odyssey infrared imaging system or enhanced chemilumi-
nescence (Thermo Scientific, MA, USA).
Insulin competition assay
Rat-1/hIR cells were grown in 100 mm dishes to 70% con-
fluence. After cell detachment using phosphate buffered
saline (PBS) containing 5 mM EDTA, the cells were incu-
bated with blocking buffer (PBS, 1% BSA and 0.1% NaN3)
for 30 min at 4◦C. Next, the cells were divided into equal
aliquots and 50 nM FITC-labeled insulin was added with
IR-A48 or native insulin. The cells were incubated for 1 h
at 4◦C to allow the binding reaction to reach equilibrium,
and the cells were washed twice with cold PBS. After fixa-
tion with PBS containing 4% paraformaldehyde for 30 min
at room temperature (RT), IR-bound FITC-labeled insulin
was measured by flow cytometry (BD FACSCantoTM II).
ELISA
Synthetic phospho-peptides at 20 pmol/100 l
(MTRDIYETD-pY-pY-RKGGKGLL, MTRDIYETD-
pY-YRKGGKGLL and MTRDIYETDY-pY-
RKGGKGLL) were covalently cross-linked to 96-well
plates (Corning, MA, USA) coated with N-oxysuccinimide
ester groups in PBS overnight at 4◦C. After blocking with
PBS containing 1% BSA for 1 h at RT, the plates were
washed once with Tris-Tween Buffered Saline (TTBS)
buffer [50 mM Tris–HCl (pH 7.6), 150 mM NaCl and
0.05% Tween-20] and incubated with primary antibodies
diluted 1:1000 in TTBS for 1 h at RT. The plates were
then washed three times in TTBS and incubated with
AP-conjugated secondary antibodies diluted 1:2000 for 1
h at RT and then washed three times with TTBS. CSPD
substrate for AP was added at 100 l per well and the
chemiluminescence was measured using a luminometer
(Luminoskan Ascent).
2-Deoxy-D-glucose uptake
The fully differentiated 3T3-L1 adipocytes were serum-
starved for 3 h in DMEMwithout FBS and glucose-starved
for 1 h in Krebs-Ringer HEPES buffer prior to insulin
or aptamer stimulation. After insulin or aptamer stimula-
tion for the indicated times, the cells were incubated with
2-deoxy[14C]glucose (0.1 Ci/ml) for 10 min and washed
three times in cold PBS containing 25 mM D-glucose. The
cells were lysed in 0.5 NNaOH and 1% sodium dodecyl sul-
phate solution and glucose uptake was measured by liquid
scintillation counter.
Cell proliferation assay
MCF-7 cells were plated at 104 cells/well in 24-well plates in
DMEM containing 10% FBS [low glucose (1 g/l) without
phenol red or pyruvate]. After 24 h, the cells were serum-
starved in DMEM containing 0.5% FBS for an additional
24 h. Next, insulin and aptamers were added and replaced
every 24 h for a total of 72 h. The cells were fixed with 4%
paraformaldehyde in PBS for 30min and stained with 1M
SYTO 60 in PBS for 1 h. The cell numbers were analyzed
by measuring the fluorescence of SYTO 60-stained DNA
using a LI-COR Odyssey infrared imaging system.
Glucose lowering effect in mice
All animal experiments were approved by the POTECH
Animal Use and Care Committee. C57Bl/6J male mice (8
weeks old) were maintained on a 12 h light/dark cycle with
regular unrestricted diets. Before insulin or aptamer injec-
tion, the mice were starved for 12 h. Insulin and aptamers
were dissolved in PBS and administrated to the mice intra-
venously. Blood was collected from the tail vein at 15, 30,
60, 90 and 120 min after injection, and blood glucose lev-
els were measured using a glucometer (Accu-Check Active;
Roche Diagnostics).
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RESULTS
Identification of an agonistic aptamer for the insulin receptor
Based upon the concept that modulating the conforma-
tion of the extracellular domain of IR can be trans-
lated to the activation of intracellular functions, we used
SELEX to develop IR aptamers capable of binding to
the extracellular domain of human IR. SELEX was per-
formed using single-strand DNA libraries that consist of
a 40mer random region and both sides of 20mer con-
stant regions and purified recombinant IR protein that
consists of the extracellular domain (His 28-Lys 944) with
a C-terminal His tag. Thymines in the random regions
were replaced with 5-[N-(1-naphthylmethyl)carboxamide]-
2′-deoxyuridine (Nap-dU) to enhance the affinity and speci-
ficity of protein–aptamer interactions (13).
To identify agonistic IR aptamers, we analyzed whether
or not the aptamers (1 mol/l) increased V-akt murine thy-
moma viral oncogene homolog (AKT) S473 phosphoryla-
tion in HEK293 cells over-expressing human IR. Although
most aptamers had no effect on insulin signaling, one IR
aptamer, IR-A48F, significantly stimulated AKT phospho-
rylation (data not shown). The sequence of IR-A48F con-
sists of 80 nt and contains 8 Nap-dUs in the random re-
gion (Figure 1A). To determine the minimal binding do-
main, we performed aptamer truncation based on the sec-
ondary structure of IR-A48F. The secondary structure pre-
dicted by the Mfold program showed that 33 internal nu-
cleotides containing 6 Nap-dUs form a stable stem-loop
structure (Figure 1B). The results of binding assay showed
that the internal stem-loop sequence (IR-A48) binds to IR
with similar affinity (3.5 nM Kd) as IR-A48F (6.9 nM Kd)
(Figure 1C). Moreover, IR-A48 appears to be highly spe-
cific to IR, because no significant binding was detected to-
ward insulin-like growth factor 1 receptor (IGF-1R), which
is structurally similar to IR (14). Thus, these results indicate
that the binding of IR-A48 is highly specific to IR, in con-
trast to insulin, which binds both IR and IGF-1R. Thus, all
subsequent experiments were performed using IR-A48.
IR-A48 binds to an allosteric site of IR
To investigate the binding properties of IR-A48, we per-
formed an insulin competition assay, followed by flow cy-
tometry. Rat-1 cells over-expressing human IR (Rat-1/hIR)
were incubated with FITC-labeled insulin (50 nmol/l) and
various concentrations of IR-A48 (0.04, 0.16, 0.63, 2.5 and
10 mol/l) and FITC fluorescence was measured to assess
changes in insulin binding. Despite its agonistic effect, IR-
A48 did not interfere with the binding of insulin to IR, even
at concentrations 200-fold higher than that of insulin (Fig-
ure 2A). This indicates that IR-A48 is an allosteric aptamer
that binds to a site distinct from the orthosteric insulin bind-
ing site.
Consistent with the allosteric binding of IR-A48, insulin-
induced downstream signaling (phosphorylation of Insulin
receptor substrate (IRS), AKT and Extracellular signal-
regulated kinases (ERK)) was not affected by IR-A48 treat-
ment in Rat-1/hIR cells (Figure 2B). However, the IR au-
tophosphorylation patterns induced by IR-A48 are differ-
ent from those produced by insulin. While both insulin
and IR-A48 induced Y1150/Y1151 phosphorylation in the
IR kinase domain that was cooperatively increased when
added in combination, total tyrosine phosphorylation of IR
was increased dramatically by insulin stimulation, but in-
creased only slightly by IR-A48 stimulation. In addition,
phosphorylation of IRSY608 andAKTS473was increased
by IR-A48, but no changes in the phosphorylation of ERK
T202/Y204 and AKT T308 were detected (Figure 2B).
Taken together, these results show that the allosteric binding
of IR-A48 induces IR autophosphorylation, but the activ-
ity seems to be biased toward specific tyrosine residues in
the IR kinase domain.
IR-A48 preferentially stimulates IR Y1150 phosphorylation
Insulin binding to IR results in autophosphorylation of
seven tyrosine residues in the intracellular -subunits (Y953
and Y960 in the juxtamembrane region; Y1146, Y1150 and
Y1151 in the kinase domain; and Y1316 and Y1322 in the
carboxy-terminus) (9). Therefore, we investigated the effect
of IR-A48 on the tyrosine phosphorylation of specific IR
residues using six commercially available antibodies (for all
residues except IR pY953, for which an antibody is not
yet available). While insulin robustly increased the phos-
phorylation of Y960, Y1146, Y1150, Y1151, Y1316 and
Y1322 of IR, IR-A48 induced increased phosphorylation
of only the Y1150/Y1151 residues in the IR kinase do-
main (Figure 3A). Despite the significant difference with
insulin, Y1150/Y1151 phosphorylation by IR-A48 was not
an off-target effect of Nap-dU containing oligonucleotides
or modified bases (Nap-dU). A scrambled aptamer (IR-
A48 RC, reverse complementary sequence of IR-A48), a
random Nap-dU DNA library used for SELEX and Nap-
dU mononucleotide had no effect on Y1150/Y1151 phos-
phorylation of IR (Supplementary Figure S1). To clearly
confirm the Y1150/Y1151-biased phosphorylation by IR-
A48, we used two different commercial antibodies to de-
tect Y1150/Y1151 phosphorylation: 10C3 (sc-81500) from
Santa Cruz and pAb (44804G) from Invitrogen. However,
in contrast to 10C3, which was previously used to detect
Y1150/Y1151 phosphorylation, the polyclonal antibody
(pAb) did not detect any phosphorylation by IR-A48 (Fig-
ure 3A).
Because Y1150 and Y1151 are independently phos-
phorylated during IR autophosphorylation, we hypothe-
sized that the two phospho-antibodies have different bind-
ing affinities for mono-pY1150, mono-pY1151 and dual-
pY1150/pY1151 (15). To clarify this issue, we determined
the binding specificity of these two antibodies by per-
forming an ELISA using synthetic phospho-peptides cor-
responding to pY1150, pY1151 or pY1150/pY1151. Al-
though the two antibodies are described as able to de-
tect dual pY1150/pY1151 (as per the provided manuals
from the manufacturer), they have significantly different
binding specificities for the mono-pY1150 peptide. The
10C3 antibody detected phosphorylation of both the dual-
pY1150/pY1151 and mono-pY1150 peptides to a similar
degree, but the polyclonal antibody (pAb) bound strongly
to only the dual pY1150/pY1151 peptide (Figure 3B).
Taken together, these data demonstrate that IR-A48 is a bi-
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Figure 1. Properties and truncation of IR-A48. (A) Comparison of the full (IR-A48F) and truncated (IR-A48) sequences of the identified agonistic IR
aptamer. ‘N’ indicates Nap-dU. (B) The secondary structure of IR-A48F was obtained from Mfold software. The dot box highlights the internal 33 nt
(IR-A48) that form the stem-loop structure. (C) Dose-dependent binding to IR and IGF-1R was measured to compare affinity between IR-A48F and
IR-A48. The dissociation constant (Kd) was determined by fitting the data to a one-site saturation model.
ased IR agonist that preferentially induces Y1150 phospho-
rylation in the IR kinase domain.
Even with the high structural similarity between IR and
IGF-1R, IR-A48 did not bind to IGF-1R (Figure 1C). To
confirm this, we used the 10C3 antibody to assess the effect
of IR-A48 on phosphorylation of IGF-1R Y1135, which is
homologous to Y1150 of IR. As expected, unlike insulin or
IGF-1, IR-A48 did not increase phosphorylation of IGF-
1R Y1135 in HeLa cells (Figure 3C).
IR-A48 differently modulates downstream signaling in 3T3-
L1 adipocytes
Next, we decided to confirm whether Y1150-biased phos-
phorylation by IR-A48 differently modulates downstream
signaling compared to insulin. The phosphorylation of ty-
rosine residues on IR -subunits plays two roles in the in-
sulin signaling process. First, phosphorylations in the ki-
nase domain (Y1146, Y1150 and Y1151) regulate IR kinase
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Figure 2. Allosteric binding of IR-A48 and insulin receptor autophosphorylation. (A) Insulin competition assay was used to confirm the allosteric binding
of IR-A48 using flow cytometry. The box plot displays the statistical distribution of FITC fluorescence from the results of the histogram. The horizontal
line in the box indicates the median value. The vertical box indicates the 25th or 75th percentile, and the vertical line indicates the maximum or minimum
value excluding outliers. (B) The effect of IR-A48 on insulin activity in Rat-1/hIR cells. Cells were stimulated with 50 nmol/l insulin or/and 200 nmol/l
IR-A48 for 10 min and phosphorylation was detected by western blotting.
activity (16). Second, phosphorylated tyrosines in the jux-
tamembrane (Y960) and C-terminal regions (Y1322) func-
tion as binding sites for adaptor proteins (17–20). Thus,
considering the Y1150-biased phosphorylation, IR-A48
would not be expected to be able to fully activate down-
stream signaling due to the low levels of phosphorylation
of other tyrosine residues.
However, unexpectedly, IR-A48 significantly activated
signaling in a manner comparable to insulin. In fully dif-
ferentiated 3T3-L1 adipocytes stimulated by insulin (50
nmol/l), the phosphorylation of IR and major insulin sig-
naling proteins such as IRS, AKT and ERK reached amax-
imal response in <5 min and gradually disappeared over
several minutes to hours (Figure 4A). In contrast to in-
sulin, IR-A48 (200 nmol/l) slowly increased the phospho-
rylation of IR (Y1150), IRS (Y608, Y632), AKT (T308,
S473), AS160 (T642), GSK3 / (S21/S9) and FOXO1/3a
(T24/T32) by 2 h and sustained the phosphorylation for
over 4 h. IR Y960 was still not significantly phosphorylated
by IR-A48 relative to insulin even after prolonged stimu-
lation of up to 8 h. The slow signaling kinetics of IR-A48
was not restricted to 3T3-L1 adipocytes, as we observed
the Y1150-biased IR phosphorylation by IR-A48 slowly
increased for 2 h and reached a plateau that was main-
tained despite prolonged stimulation for over 8 h in Rat-
1/hIR cells (Supplementary Figure S2).Moreover, Nap-dU
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Figure 3. Y1150-biased phosphorylation in the IR kinase domain by IR-
A48. (A) The phosphorylation of six tyrosine residues of IR was analyzed
using specific phospho-antibodies. Rat-1/hIR cells were stimulated with
200 nmol/l IR-A48 and 50 nmol/l insulin for 10 min. (B) Specificity of the
phospho-antibodies 10C3 and pAb for mono-pY1150, mono-pY1151 and
dual-pY1150/pY1151 peptides. 10C3 is a monoclonal antibody purchased
from Santa Cruz (sc-81500) and pAb is a polyclonal antibody purchased
from Invitrogen (44804G). Data represent the mean ± S.E. of four bio-
logical replicates and similar results were obtained from two independent
experiments. Black bar, 10C3; white bar, pAb. (C) Non-cross-reactivity of
IR-A48 with IGF-1R. Following incubation of HeLa cells with 50 nmol/l
IGF-1, 100 nmol/l insulin and 1 mol/l IR-A48 for 1 h, IGF-1R was
immunoprecipitated. The monoclonal antibody 10C3 was used to detect
pY1135 of IGF-1R.
containing oligonucleotides and Nap-dU mononucleotide
also did not stimulate downstream signaling in 3T3-L1
adipocytes (Supplementary Figure S3).
Importantly, IR-A48 showed biased activity toward sub-
sets of the insulin signaling pathway. The level of AKT
phosphorylation induced by IR-A48 was biased toward
S473. IR-A48-inducedAKTS473 phosphorylation reached
98% of the level of phosphorylation induced by insulin, but
AKT T308 phosphorylation stayed at just 37% of the level
induced by insulin (Figure 4A–C). In addition, ERK was
only slightly activated by IR-A48 (Figure 4A and D). These
results indicate that IR-A48 can activate signaling down-
stream of IR, but that the signaling cascades activated by
IR-A48 are markedly different from those activated by in-
sulin.
IR-A48 does not induce proliferation of MCF-7 cancer cells
The MAPK pathway is one of the major signaling routes
induced by IR autophosphorylation and is responsible for
cell proliferation (21,22). Of particular importance is the ef-
fect of insulin on cell proliferation in some cancer cell lines
(23,24). Because IR-A48 did not activate the MAPK path-
way (Figure 4A and D), we investigated whether IR-A48
has an effect on cell proliferation.
To analyze the mitogenic potency of IR-A48, we per-
formed growth assays in the MCF-7 human breast cancer
cell line, which is widely used to study the proliferative ef-
fect of insulin. In MCF-7 cells, insulin increased cell pro-
liferation by up to 2.1-fold, but IR-A48 had no effect on
cell proliferation (Figure 5A).Moreover, IR-A48 (1mol/l)
did not cooperatively potentiate insulin-induced cell pro-
liferation, even when the cells were co-incubated with in-
creasing concentrations of insulin (Figure 5B). To rule out
the possibility that IR-A48 does not activate IR in MCF-7
cells, we assessed the activation of IR and subsequent down-
stream signaling inMCF-7 cells. Consistent with the results
in 3T3-L1 adipocytes, IR-A48 preferentially induced phos-
phorylation of IR Y1150 and AKT S473, but had no effect
on IGF1-R, AKT T308 and ERK (Figure 5C). These data
demonstrate that the signaling pathway induced by IR-A48
is completely segregated from the mitogenic insulin-IR axis.
IR-A48 stimulates glucose uptake in 3T3-L1
The metabolic function of IR is mainly regulated by the
IRS-AKT pathway (25). Glucose uptake is the most im-
portant metabolic function of insulin. Insulin-induced IR
autophosphorylation increases glucose uptake by induc-
ing GLUT4 exocytosis in adipose tissue and muscle. Many
studies confirmed that AKT functions as a central hub
for glucose uptake by acting as a mediator between in-
sulin signaling and regulators ofGLUT4 translocation (10).
Because IR-A48 stimulated AKT S473 phosphorylation
in 3T3-L1 adipocytes (Figure 4A and B), we examined
whether IR-A48 stimulates glucose uptake.
To investigate the effect of IR-A48-induced signaling
on glucose uptake, we measured 2-deoxy-glucose uptake
in 3T3-L1 adipocytes after time-dependent stimulation.
Despite IR Y1150-biased phosphorylation, IR-A48 (200
nmol/l) increased glucose uptake to the same extent as in-
sulin (50 nmol/l). In addition, consistent with its allosteric
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Figure 4. IR-A48 stimulated IR signaling produces distinct kinetic and phosphorylation patterns. (A) Fully differentiated 3T3-L1 adipocytes were stim-
ulated with 50 nmol/l insulin and 200 nmol/l IR-A48 for the indicated times. The phosphorylation of major insulin signaling proteins was measured by
western blotting. pAS160, pFOXO1/3a and pSHC were detected using ECL; the rest of the proteins were detected by an Odyssey infrared imaging system
(LI-COR). The kinetics of (B) pAKT S437, (C) pAKTT308 and (D) pERKT202/Y204 are presented as the mean± S.E. of three independent experiments
and data were normalized to band intensity of each negative control (NT) to determine fold of basal.
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Figure 5. Proliferation of MCF-7 cells was not stimulated by IR-A48. (A)
The effect of IR-A48 on cell proliferation was compared to that of in-
sulin. MCF-7 cells were incubated with increasing concentrations of IR-
A48 or insulin for 72 h. (B) To investigate whether IR-A48 can potentiate
insulin-induced proliferation, cells were incubated with 1 mol/l IR-A48
and increasing concentrations of insulin for 72 h. A proliferation assay was
performed by measuring the amount of SYTO60-stained DNA using an
Odyssey infrared imaging system (LI-COR) and the data were fitted to a
four-parameter logistic equation. Data are presented as the mean± S.E. of
four biological replicates and similar results were obtained from three in-
dependent experiments. (C) The effect of IR-A48 in MCF-7 cells. MCF-7
cells were treated with 100 nmol/l insulin and 1 mol/l IR-A48 for 5 min,
1 and 2 h.
binding to IR (Figure 2A), insulin and IR-A48 coopera-
tively increased glucose uptake when added in combination
(Figure 6A). Similar to the phosphorylation status of IR
Y1150 and AKT S473 (Figure 4A), the kinetic of glucose
uptake by IR-A48 was also quite different from that of in-
ulin. After insulin stimulation, glucose uptake reachedmax-
imal response at 30 min to 1 h and was sustained for up
to 2 h before slowly decreasing to a level less than half the
maximum after 8 h. However, the glucose uptake by IR-
A48 slowly increased over 4 h and was sustained over 8 h
(Figure 6A). IR-A48 also increased glucose uptake in L6 rat
myoblast overexpressing GLUT4, which indicates that IR-
A48 has cross activity to human, mouse and rat IR (Supple-
mentary Figure S4). However, Nap-dU containing oligonu-
cleotides and Nap-dU mononucleotide did not induce glu-
cose uptake in 3T3-L1 adipocytes despite prolonged stimu-
lation for 4 h (Supplementary Figure S5).
In spite of the slower kinetics, IR-A48 fully induced glu-
cose uptake at high concentrations. We measured glucose
uptake induced by insulin and IR-A48 in a dose-dependent
manner based on the time points that showed maximal
response (30 min for insulin and 4 h for A48). At maxi-
mal concentrations, both IR-A48 and insulin showed sim-
ilar saturated levels of glucose uptake (4.2- and 4-fold, re-
spectively; Figure 6B). However, IR-A48 exponentially in-
creased glucose uptake in the range of 20–200 nmol/l (Hill
coefficient: 2.37) in contrast to insulin, which produced a
gradual dose-response curve (Hill coefficient: 0.77). Conse-
quently, the EC50 value for IR-A48was higher (66.2 nmol/l)
than that for insulin (8.9 nmol/l), although the EC95 value
for IR-A48 (202.4 nmol/l) was slightly lower than that for
insulin (261.9 nmol/l). Similar to the glucose uptake pat-
terns, the dose-dependent phosphorylation of AKT S473
and IRSY608 by IR-A48 also showed an exponential curve
(Supplementary Figure S6). It is still unclear why IR-A48
produces an exponential dose-response curve compared to
insulin, but these data clearly indicate that IR-A48 can fully
stimulate glucose uptake.
Phosphoinositide 3-kinase dependency of IR-A48 on glucose
uptake
In insulin signaling cascades, phosphoinositide 3-kinase
(PI3K) is fully responsible forAKTactivation (26,27). AKT
T308 is phosphorylated by phosphoinositide-dependent ki-
nase 1 (PDK1), which is achieved by phosphatidylinositol
(3,4,5)-trisphosphate-mediated membrane recruitment of
PDK1. The activation of mammalian target of rapamycin
complex 2 (mTORC2), which is the main kinase responsible
for phosphorylation of AKT S473, also requires PI3K ac-
tivity. Accordingly, PI3K inhibitors such as LY294002 block
not only AKT phosphorylation, but also AKT-mediated
cellular functions such as glucose uptake (28).
To investigate the PI3K-dependency of IR-A48 induced
events, we measured glucose uptake and AKT phospho-
rylation in 3T3-L1 adipocytes after pre-incubation with a
PI3K inhibitor (LY294002) for 1 h. Not only glucose uptake
induced by IR-A48 (200 nmol/l) was significantly blocked
by LY294002, regardless of stimulation time (30 min and 2
h), but AKT phosphorylation by IR-A48 was also inhib-
ited (Figure 6C and D). Therefore, as with insulin, AKT
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Figure 6. IR-A48 stimulates glucose uptake through the PI3K pathway in 3T3-L1 adipocytes. (A) 2-Deoxy-D-glucose uptake was measured following
incubation of adipocytes with 50 nmol/l insulin or 200 nmol/l IR-A48 for 5 min, 10 min, 30 min, 1 h, 2 h, 4 h and 8 h. (B) Cells were treated with increasing
doses of insulin and IR-A48 for 30 min (insulin) or 4 h (IR-A48). To determine the EC50, EC95 and Hill coefficient, data were fitted to a four-parameter
logistic equation. (C) Before insulin or IR-A48 stimulation, cells were pre-incubated with 20 mol/l LY294002 for 1 h. 2-deoxy-D-glucose uptake was
measured after 30 min (gray bar) and 2 h (black bar). The data for glucose uptake are presented as the mean ± S.E. of three biological replicates and
similar results were obtained from three independent experiments. (D) AKT phosphorylation was measured by western blotting to assess the effect of
PI3K inhibition on IR-A48-induced phosphorylation.
phosphorylation and glucose uptake stimulated by IR-A48
in 3T3-L1 adipocytes are dependent on PI3K activity.
IR-A48 lowers blood glucose in mice
To confirm our results in vivo, we evaluated the effect of
IR-A48 on blood glucose levels in mice. To prevent rapid
degradation of the aptamer by 3′ exonucleases in the blood,
inverted deoxy-thymidine (idT) was incorporated at the 3′-
end of IR-A48. In mouse serum, idT conjugated IR-A48
was sufficiently stable to observe short-term in vivo glucose
lowering (t1/2 = 82 min) (Supplementary Figure S7). After
fasting for 12 h, IR-A48 at doses of 10, 5 and 2.5mg/kgwere
administered to mice through tail vein injection and blood
glucose levels were measured for up to 120 min. At 30 min
after injection, mice treated with 10 mg/kg IR-A48 exhib-
ited significantly lowered blood glucose levels (59%of initial
level), comparable to that achieved by administration of 0.6
unit/kg insulin (49% of initial level) (Figure 7). Notably, in
contrast to insulin-treated mice, whose blood glucose levels
recovered after 30 min, mice treated with IR-A48 exhibited
continuously decreased blood glucose levels (53% of initial
level) for 1 h, and the recovery of blood glucose levels oc-
curred much more slowly than following insulin treatment,
reflecting the in vitro data (Figure 6A). In addition, consis-
tent with cell experiments, a scrambled aptamer (IR-A48
RC) also did not decrease blood glucose level in mice (Sup-
plementary Figure S8). Thus, this result clearly shows that
IR-A48 is effective both in vivo and in vitro, and demon-
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Figure 7. IR-A48 lowers blood glucose levels in mice to the same degree
as insulin. Insulin (0.6 unit/kg), IR-A48 (2.5, 5 and 10 mg/kg) and PBS
were administered to 12 h fasted C57Bl/6J mice by tail vein injection and
blood glucose levels were measured at 15, 30, 60, 90 and 120 min after in-
jection. The data were normalized to glucose levels determined just before
injection. Values are given as the means ±S.E. (n = 5 mice/group).
strates that the allosteric modulation of IR by IR-A48 can
control blood glucose levels independent of insulin.
DISCUSSION
In this study, we identified an agonistic IR aptamer, IR-
A48, which is highly specific for IR without cross-activity
for IGF-1R. IR-A48 binds to an allosteric site distinct from
the orthosteric site for insulin binding and preferentially
stimulates Y1150 phosphorylation in the IR kinase domain.
Moreover, we demonstrated that the allosteric binding of
IR-A48 not only stimulates activation of the IRS-AKT
S473 pathway and glucose uptake in 3T3-L1 adipocytes,
but also successfully lowers blood glucose levels in mice in a
manner similar to insulin. However, unlike stimulation with
insulin, activation of the MAPK pathway and the prolifer-
ation of MCF-7 cancer cells were not induced by IR-A48.
Taken together, these results demonstrate that IR-A48 is a
biased agonist of IR that selectively stimulates themetabolic
activity of the receptor (glucose uptake) without mitogenic
action (proliferation).
This is the first study to show that aptamer–protein in-
teractions can not only differentially modulate receptor au-
tophosphorylation (IR Y1150), but also induce specific sig-
naling pathways and functional selectivity. To modulate re-
ceptor functions involved in the immune response, some
dimeric or multivalent ligands using non-functional ap-
tamers were developed. However, their activity is based
on receptor oligomerization mediated by aptamer bridges,
rather than by a change in receptor conformation in-
duced by aptamer–receptor interactions (29–31). Until now,
aptamer-mediated receptor activation has been reported
only for an aptamer that binds tropomyosin receptor ki-
nase B (TrkB). However, this aptamer not only acts as
a simple partial agonist that is not functionally different
from an endogenous ligand, Brain Derived Neurotrophic
Factor(BDNF), but also partially inhibits BDNF-mediated
TrkB activation (32). The concept of a biased agonist able
to selectively modulate receptor functions has been well-
established and several studies described small chemicals,
peptides and antibodies that act as biased agonists (33,34).
Our results indicate that it is possible to develop allosteric-
biased agonists to a specific membrane receptor through
SELEX.
A key aspect of biased agonists is their capacity to pro-
vide a therapeutic advantage for treating diseases by avoid-
ing on-target adverse effects that arise from the activation of
undesirable signaling pathways (33,34). In this respect, bi-
ased IR modulation is considered a valuable modality for
diabetes care. Diabetes mellitus patients suffer from defi-
cient secretion of insulin resulting from pancreatic beta-cell
death (Type 1 diabetes), or insulin resistance, in which pe-
ripheral tissues fail to respond to insulin stimulation (Type
2 diabetes). To date, a variety of insulin analogs that have
modified amino acid sequences have been successfully used
in diabetes patients for normal glycemic control. However,
insulin treatment is also considered to promote cell pro-
liferation and the amino acid modifications of some in-
sulin analogs increase their binding affinity and activation
of IGF1-R (23,35,36). Accordingly, long-term use of insulin
analogs for diabetes care has raised concerns regarding in-
creased cancer risk (37) and several epidemiological reports
showed correlations between prolonged insulin treatment
and increased cancer risk (38–42). Therefore, the develop-
ment of a biased IR agonist that selectively induces glucose
uptake without a mitogenic effect would present a viable al-
ternative to insulin therapy (43). IR-A48 raises the possibil-
ity of the use of a biased IR agonist to control blood glucose
without the potential increase in cancer risk. In particular,
the high specificity of IR-A48 for IR (and not IGF-1R) and
its ability to bind allosterically without interfering with in-
sulin binding are notable advantages as a therapeutic agent
for diabetes care. We believe that IR-A48 represents a novel
strategy for allosterically facilitating insulin action and im-
proving glycemic control in diabetes patients.
The biased nature of IR-A48-mediated IR modulation
likely results from the altered structural state induced by
the allosteric binding of IR-A48. Evidence for this comes
from the pattern of IR autophosphorylation induced by IR-
A48 binding compared to insulin. In our study, we demon-
strated that IR-A48 preferentially stimulates Y1150 phos-
phorylation in the IR kinase domain. Interestingly, the cur-
rent activation model for IR autophosphorylation cannot
sufficiently explain how Y1150-biased phosphorylation oc-
curs in the absence of Y1146 and 1151 phosphorylation.
Currently, phosphorylation of Y1146, Y1150 and Y1151
in the IR kinase domain is believed to occur via trans-
autophosphorylation (44,45). Y1146, Y1150 andY1151 are
located in the activation loop (A-loop) in the IR kinase do-
main (46). According to the current model, insulin bind-
ing induces a conformational change that causes the IR ki-
nase domains to approach each other, which activates the
IR kinase by phosphorylating the opposite three tyrosine
residues in the A-loop.Moreover, biochemical data demon-
strate that artificial dimerization or aggregation of the IR
kinase domain mainly leads to tri-phosphorylation of the
A-loop (pY1146-pY1150-pY1151) (15). One plausible ex-
planation for the observed IR-A48-mediated Y1150-biased
phosphorylation is the presence of an independent mecha-
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nism specific for Y1150 phosphorylation that is not related
to trans-phosphorylation. However, this remains unknown
due to the absence of structural evidence to clarify how
the allosteric binding of IR-A48 differentially modulates IR
conformation. Thus, a major question to be addressed in
further studies will be the identification of the binding site
of IR-A48 and the subsequent change in IR conformation.
The Y1150-biased phosphorylation induced by IR-A48
also differentially regulates signaling beyond simple recep-
tor modulation. The data presented here reveal that IR-
A48 can dramatically increase the phosphorylation of pro-
teins in the IRS-AKTpathway such as IRS-1, AKT,AS160,
FOXO1/3a and GSK3 in 3T3-L1 adipocytes. Conversely,
phosphorylation of Src homology 2 domain containing
transforming protein (SHC) and ERK in the MAPK path-
way was not significantly stimulated by IR-A48. Previous
studies on agonists that target the extracellular domain
of IR reported similar biased signaling and functional se-
lectivity. For instance, the synthetic peptide S597 and al-
losteric antibody XMetA induced higher activation of the
IRS-AKT pathway than the MAPK pathway. Moreover,
S597 induced the activation of glycogen synthesis in L6 my-
oblast cells and XMetA markedly improved glycemic con-
trol in diabetic model mice, but neither had an effect on
cell proliferation (47,48). However, at present, the mecha-
nism that mediates biased signaling and functional selec-
tivity at the receptor level remains unknown. Our data im-
ply that the IR Y1150-biased phosphorylation by IR-A48
is a unique property involved in functional selectivity. Al-
though S597 and XMetA have signaling properties simi-
lar to IR-A48, IR Y1150-biased phosphorylation was not
documented, because only total tyrosine phosphorylation
was observed. Thus, mapping the IR tyrosine phosphoryla-
tion induced by other IR agonists will be necessary. If they
share the sameY1150-biased activity, this would be clear ev-
idence that IR Y1150 phosphorylation is a determinant of
functional selectivity. In addition, the extracellular motif or
structure of IR that regulates metabolism-specific signaling
could be identified by comparing binding sites and analyz-
ing the conformational changes induced by these agonists.
We also observed that AKT phosphorylation by IR-
A48 is biased toward S473 rather than T308. The find-
ing that IR-A48 sufficiently stimulated glucose uptake in
3T3-L1 adipocytes suggests that AKT T308 phosphory-
lation is not critically involved in glucose uptake. The
specific roles of T308 and S473 in AKT activation are
still unclear, but AKT kinase is fully activated when both
residues are phosphorylated (49). Although the critical role
of AKT in insulin-induced glucose uptake was verified us-
ing dominant-negative and constitutively-active mutants,
the specific roles of S473 and T308 in this process have
not been sufficiently studied (50–52). However, some stud-
ies showed that T308 and S473 have different effects on
the phosphorylation ofAKT substrates andAKT-mediated
functions. For instance, disruption of mTORC2, which
phosphorylates AKT S473, impairs FOXO1/3a phospho-
rylation, but has no effect on GSK3 and TSC2 phospho-
rylation (53,54). In addition, functionally, only AKT T308
phosphorylation, not S473, is correlated with survival of
acute myeloid leukemia patients and AKT kinase activity
in human non-small cell lung cancer (55,56). Thus, in 3T3-
L1 adipocytes, AKT substrates that are involved in glu-
cose uptake may be mainly regulated by AKT S473 rather
than T308. Consistent with this, fat cell-specific ablation
of Rictor, a subunit of mTORC2, in mice significantly im-
paired insulin-induced glucose uptake even though AKT
T308 phosphorylation was maintained (57). Unfortunately,
how IRY1150-biased phosphorylation leads to AKT S473-
biased phosphorylation remains an open question to be
solved through further research.
Our understanding of the biased IR modulation by IR-
A48 is incomplete, with a range of questions remaining to be
answered. However, the concept of allosteric aptamers able
to selectively modulate receptor functions suggests a novel
strategy for research on receptor modulation and the devel-
opment of more effective therapeutics. Advances in DNA
synthetic methods and automation of the SELEX process
make it possible to generatemultiple target-specific aptamer
libraries withinweeks. In contrast to conventional screening
using large numbers of non-specific compounds, aptamer
technology has a crucial advantage in that it is able to gener-
ate candidatemolecules with outstanding affinity and speci-
ficity to targeted receptors. Our study provides new direc-
tion for aptamer application: the development of allosteric
receptor agonists able to modulate specific functions of the
target receptors.
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